TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community Case Management for Early Psychosis: is Two Year an Optimal Duration? A Randomized Controlled Study
Brief Summary: A total of 160 subjects, who aged 18-35 and had completed the first 2 years of case management in the EASY programme will be randomized in 1:1 ratio into either (1) receiving an additional year of case management, or (2) terminating case management for the next 12 months. The current study aims to investigate whether an additional year of case management in year 3 will confer additional benefits in outcome, in terms of functioning, symptoms, quality of life and health economics.


Options:
A: Arm Label: case management (4 yrs); Type: EXPERIMENTAL; Interventions: Behavioral: stage-specific case-management | Arm Label: case management (2 yrs) and standard care (2 yrs); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: stage-specific case-management | Arm Label: standard care (4 yrs); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: stage-specific case-management; Assigned to Arm(s): case management (2 yrs) and standard care (2 yrs), case management (4 yrs)
B: Arm Label: Individual psychoeducation; Type: EXPERIMENTAL; Interventions: Other: Individual psychoeducation | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control | Intervention Type: OTHER; Name: Individual psychoeducation; Assigned to Arm(s): Individual psychoeducation
C: Arm Label: Case Management (1 year); Type: EXPERIMENTAL; Interventions: Behavioral: Community Case Management | Arm Label: Standard Care (1 year); Type: NO_INTERVENTION; Interventions: Behavioral: Community Case Management | Intervention Type: BEHAVIORAL; Name: Community Case Management; Assigned to Arm(s): Case Management (1 year), Standard Care (1 year)
D: Arm Label: 5 year; Type: EXPERIMENTAL; Interventions: Behavioral: OPUS 5 years | Arm Label: 2 years of OPUS treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 2 years OPUS treatment | Intervention Type: BEHAVIORAL; Name: 2 years OPUS treatment; Assigned to Arm(s): 2 years of OPUS treatment | Intervention Type: BEHAVIORAL; Name: OPUS 5 years; Assigned to Arm(s): 5 year

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Randomized Double-Blind Placebo-Controlled Trial of the Omega-3 Fatty Acids Eicosapentaenoic (EPA) and Docosahexaenoic Acid (DHA) in Pediatric Sickle Cell Disease (SCD)
Brief Summary: The purpose of the study is to determine the effectiveness of LOVAZA (fish oil capsules) to decrease inflammation in children and adolescents with Sickle Cell Disease (SCD). It has been found that besides the damage caused by sickle red blood cells themselves, the inflammatory response that occurs in SCD patients could potentially play a significant role in the occurrence of painful episodes or pain crises. The investigators will also study whether the subject/caregiver feels that there is an improvement in the child's quality of life by taking the medication. Besides the effect of LOVAZA on inflammation,the investigators are also testing whether the drug will have a beneficial effect on blood clotting ability (which is known to be increased in SCD) and on the anemia (low red blood cells) that is part of the disease entity.


Options:
A: Arm Label: L-glutamine; Type: EXPERIMENTAL; Interventions: Drug: L-glutamine | Arm Label: 100% maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: L-glutamine; Assigned to Arm(s): L-glutamine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 100% maltodextrin
B: Arm Label: L-Arginine; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Arm Label: Loading Dose and L-Arginine; Type: EXPERIMENTAL; Interventions: Drug: L-arginine, Drug: L-arginine Loading Dose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): L-Arginine, Loading Dose and L-Arginine | Intervention Type: DRUG; Name: L-arginine Loading Dose; Assigned to Arm(s): Loading Dose and L-Arginine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Low Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arginine | Arm Label: High Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arginine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Arginine; Assigned to Arm(s): High Dose, Low Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: LOVAZA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) | Arm Label: Placebo capsule; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Capsules | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA); Assigned to Arm(s): LOVAZA | Intervention Type: OTHER; Name: Placebo Capsules; Assigned to Arm(s): Placebo capsule

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multicenter, Randomized, Double Blind, Dose Escalating/ De Escalating Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of a Single Dose of Sustained Release Encapsulated Bupivacaine (SKY0402) in the Management of Postoperative Pain in Subjects Undergoing Inguinal Hernia Repair
Brief Summary: The primary objective of this study was to determine the appropriate dose of SKY0402 for the management of postoperative pain following inguinal hernia repair. This study evaluated the safety, efficacy, and pharmacokinetics of SKY0402 compared with a 100 mg dose of bupivacaine HCl for the treatment of postoperative pain in subjects undergoing inguinal hernia repair. Study drug was administered by surgical wound infiltration at the end of the hernia repair procedure.


Options:
A: Arm Label: SKY0402; Type: EXPERIMENTAL; Interventions: Drug: SKY0402 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SKY0402; Assigned to Arm(s): SKY0402 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Bupivacaine HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: SKY0402 | Arm Label: SKY0402; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupivacaine HCl | Intervention Type: DRUG; Name: SKY0402; Assigned to Arm(s): Bupivacaine HCl | Intervention Type: DRUG; Name: Bupivacaine HCl; Assigned to Arm(s): SKY0402
C: Arm Label: IV Morphine Sulfate or Sponsor-approved Equivalent; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV morphine sulfate or Sponsor-approved equivalent | Arm Label: EXPAREL; Type: EXPERIMENTAL; Interventions: Drug: EXPAREL | Intervention Type: DRUG; Name: IV morphine sulfate or Sponsor-approved equivalent; Assigned to Arm(s): IV Morphine Sulfate or Sponsor-approved Equivalent | Intervention Type: DRUG; Name: EXPAREL; Assigned to Arm(s): EXPAREL
D: Arm Label: Bupivacaine HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupivacaine HCl | Arm Label: SKY0402; Type: OTHER; Interventions: Drug: SKY0402 | Intervention Type: DRUG; Name: Bupivacaine HCl; Assigned to Arm(s): Bupivacaine HCl | Intervention Type: DRUG; Name: SKY0402; Assigned to Arm(s): SKY0402

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial - Star AF II Study
Brief Summary: This investigation is designed with the hypothesis that combined PV Antral Isolation and Ablation of Complex Fractionated Electrograms (PVI+CFE) approach will offer a higher success rate compared to the Wide Circumferential Pulmonary Vein Antrum Isolation (PVI) approach and to the Combined PV Antral Isolation and Empiric Linear Ablation (PVI+Lines) approach.


Options:
A: Arm Label: PVI + Lines Ablation; Type: EXPERIMENTAL; Interventions: Procedure: PVI + Lines ablation | Arm Label: PVI Ablation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PVI | Arm Label: PVI + CFE; Type: EXPERIMENTAL; Interventions: Procedure: PVI + CFE ablation | Intervention Type: PROCEDURE; Name: PVI + Lines ablation; Assigned to Arm(s): PVI + Lines Ablation | Intervention Type: PROCEDURE; Name: PVI; Assigned to Arm(s): PVI Ablation | Intervention Type: PROCEDURE; Name: PVI + CFE ablation; Assigned to Arm(s): PVI + CFE
B: Arm Label: 10 mg Empagliflozin; Type: EXPERIMENTAL; Interventions: Drug: Empagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Empagliflozin; Assigned to Arm(s): 10 mg Empagliflozin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education
D: Arm Label: Left Atrial Ablation; Type: ACTIVE_COMPARATOR; Interventions: Device: Left atrial ablation | Arm Label: Rate or Rhythm Control Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rate or Rhythm Control Therapy | Intervention Type: DEVICE; Name: Left atrial ablation; Assigned to Arm(s): Left Atrial Ablation | Intervention Type: DRUG; Name: Rate or Rhythm Control Therapy; Assigned to Arm(s): Rate or Rhythm Control Therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial - Star AF II Study
Brief Summary: This investigation is designed with the hypothesis that combined PV Antral Isolation and Ablation of Complex Fractionated Electrograms (PVI+CFE) approach will offer a higher success rate compared to the Wide Circumferential Pulmonary Vein Antrum Isolation (PVI) approach and to the Combined PV Antral Isolation and Empiric Linear Ablation (PVI+Lines) approach.


Options:
A: N/A
B: Arm Label: PVI + Lines Ablation; Type: EXPERIMENTAL; Interventions: Procedure: PVI + Lines ablation | Arm Label: PVI Ablation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PVI | Arm Label: PVI + CFE; Type: EXPERIMENTAL; Interventions: Procedure: PVI + CFE ablation | Intervention Type: PROCEDURE; Name: PVI + Lines ablation; Assigned to Arm(s): PVI + Lines Ablation | Intervention Type: PROCEDURE; Name: PVI; Assigned to Arm(s): PVI Ablation | Intervention Type: PROCEDURE; Name: PVI + CFE ablation; Assigned to Arm(s): PVI + CFE
C: Arm Label: Catheter Ablation; Type: EXPERIMENTAL; Interventions: Procedure: Catheter ablation of persistent atrial fibrillation | Arm Label: Medical treatment alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Medical treatment alone | Intervention Type: PROCEDURE; Name: Catheter ablation of persistent atrial fibrillation; Assigned to Arm(s): Catheter Ablation | Intervention Type: DRUG; Name: Medical treatment alone; Assigned to Arm(s): Medical treatment alone
D: Arm Label: Drug Treatment; Type: ACTIVE_COMPARATOR; Interventions: Device: Radiofrequency ablation, antiarrhythmic drugs, Drug: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs | Arm Label: ThermoCool Radiofrequency Catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: Radiofrequency ablation, antiarrhythmic drugs, Device: ThermoCool Radiofrequency Catheter | Intervention Type: DEVICE; Name: Radiofrequency ablation, antiarrhythmic drugs; Assigned to Arm(s): Drug Treatment, ThermoCool Radiofrequency Catheter | Intervention Type: DRUG; Name: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs; Assigned to Arm(s): Drug Treatment | Intervention Type: DEVICE; Name: ThermoCool Radiofrequency Catheter; Assigned to Arm(s): ThermoCool Radiofrequency Catheter

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: IRB-HSR# 13957: IV Lidocaine for Patients Undergoing Primary Breast Cancer Surgery: Effects on Postoperative Recovery and Cancer Recurrence
Brief Summary: The purpose of this study is to determine whether a local anesthetic drug (lidocaine) given during anesthesia intravenously (IV) through a needle in your vein,), can:

1. Help decrease pain after surgery.
2. Have you need less pain medication.
3. Have less side effects like nausea and vomiting following your surgery.
4. Help to prevent chronic pain.
5. Affect recurrence of cancer after surgery.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: chirocaine (Levobupivacaine) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: sodium chloride | Intervention Type: DRUG; Name: chirocaine (Levobupivacaine); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sodium chloride; Assigned to Arm(s): 2
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Lidocaine; Type: EXPERIMENTAL; Interventions: Drug: Lidocaine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): Lidocaine
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: ketamine | Intervention Type: DRUG; Name: ketamine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1
D: Arm Label: Group L; Type: EXPERIMENTAL; Interventions: Drug: Systemic intravenous lidocaine infusion | Arm Label: Group C; Type: PLACEBO_COMPARATOR; Interventions: Drug: normal saline infusion | Intervention Type: DRUG; Name: Systemic intravenous lidocaine infusion; Assigned to Arm(s): Group L | Intervention Type: DRUG; Name: normal saline infusion; Assigned to Arm(s): Group C

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: IRB-HSR# 13957: IV Lidocaine for Patients Undergoing Primary Breast Cancer Surgery: Effects on Postoperative Recovery and Cancer Recurrence
Brief Summary: The purpose of this study is to determine whether a local anesthetic drug (lidocaine) given during anesthesia intravenously (IV) through a needle in your vein,), can:

1. Help decrease pain after surgery.
2. Have you need less pain medication.
3. Have less side effects like nausea and vomiting following your surgery.
4. Help to prevent chronic pain.
5. Affect recurrence of cancer after surgery.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: chirocaine (Levobupivacaine) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: sodium chloride | Intervention Type: DRUG; Name: chirocaine (Levobupivacaine); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sodium chloride; Assigned to Arm(s): 2
B: Arm Label: Group L; Type: EXPERIMENTAL; Interventions: Drug: Systemic intravenous lidocaine infusion | Arm Label: Group C; Type: PLACEBO_COMPARATOR; Interventions: Drug: normal saline infusion | Intervention Type: DRUG; Name: Systemic intravenous lidocaine infusion; Assigned to Arm(s): Group L | Intervention Type: DRUG; Name: normal saline infusion; Assigned to Arm(s): Group C
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Intervention Type: PROCEDURE; Name: perioperative epidural catheter; Assigned to Arm(s): 1, 2, 3, 4, 5
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Lidocaine; Type: EXPERIMENTAL; Interventions: Drug: Lidocaine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): Lidocaine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: IRB-HSR# 13957: IV Lidocaine for Patients Undergoing Primary Breast Cancer Surgery: Effects on Postoperative Recovery and Cancer Recurrence
Brief Summary: The purpose of this study is to determine whether a local anesthetic drug (lidocaine) given during anesthesia intravenously (IV) through a needle in your vein,), can:

1. Help decrease pain after surgery.
2. Have you need less pain medication.
3. Have less side effects like nausea and vomiting following your surgery.
4. Help to prevent chronic pain.
5. Affect recurrence of cancer after surgery.


Options:
A: Arm Label: Group L; Type: EXPERIMENTAL; Interventions: Drug: Systemic intravenous lidocaine infusion | Arm Label: Group C; Type: PLACEBO_COMPARATOR; Interventions: Drug: normal saline infusion | Intervention Type: DRUG; Name: Systemic intravenous lidocaine infusion; Assigned to Arm(s): Group L | Intervention Type: DRUG; Name: normal saline infusion; Assigned to Arm(s): Group C
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: lidocaine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: lidocaine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Lidocaine; Type: EXPERIMENTAL; Interventions: Drug: Lidocaine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): Lidocaine
D: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: lidocaine | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupivacaine with hydromorphone | Intervention Type: DRUG; Name: bupivacaine with hydromorphone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: lidocaine; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
Brief Summary: The purpose of this study is to determine if treatment with paclitaxel plus AMG 386 is superior to paclitaxel plus placebo in women with recurrent partially platinum sensitive or resistant epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer.

AMG 386 is a man-made medication that is designed to stop the development of blood vessels in cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called angiogenesis, to obtain a supply of oxygen and nutrients to grow.


Options:
A: Arm Label: BIBF 1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120, Drug: Paclitaxel, Drug: Carboplatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): BIBF 1120 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): BIBF 1120 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): BIBF 1120
B: Arm Label: AMG 386; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: AMG 386 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: AMG 386 Placebo, Drug: Paclitaxel | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): AMG 386 | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): AMG 386 Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): AMG 386 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): AMG 386 Placebo
C: Arm Label: Combination navicixizumab + paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: navicixizumab, Device: Xerna™ TME Panel | Arm Label: Paclitaxel monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Xerna™ TME Panel | Arm Label: Navicixizumab monotherapy; Type: EXPERIMENTAL; Interventions: Drug: navicixizumab, Device: Xerna™ TME Panel | Intervention Type: DRUG; Name: navicixizumab; Assigned to Arm(s): Combination navicixizumab + paclitaxel, Navicixizumab monotherapy | Intervention Type: DEVICE; Name: Xerna™ TME Panel; Assigned to Arm(s): Combination navicixizumab + paclitaxel, Navicixizumab monotherapy, Paclitaxel monotherapy
D: Arm Label: paclitaxel and pazopanib; Type: EXPERIMENTAL; Interventions: Drug: paclitaxel, Drug: pazopanib | Arm Label: paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): paclitaxel, paclitaxel and pazopanib | Intervention Type: DRUG; Name: pazopanib; Assigned to Arm(s): paclitaxel and pazopanib

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
Brief Summary: The purpose of this study is to determine if treatment with paclitaxel plus AMG 386 is superior to paclitaxel plus placebo in women with recurrent partially platinum sensitive or resistant epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer.

AMG 386 is a man-made medication that is designed to stop the development of blood vessels in cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called angiogenesis, to obtain a supply of oxygen and nutrients to grow.


Options:
A: Arm Label: PLD; Type: ACTIVE_COMPARATOR; Interventions: Drug: PLD 40mg/m2 ivgtt q4w | Arm Label: PLD + Apatinib; Type: EXPERIMENTAL; Interventions: Drug: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd | Intervention Type: DRUG; Name: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd; Assigned to Arm(s): PLD + Apatinib | Intervention Type: DRUG; Name: PLD 40mg/m2 ivgtt q4w; Assigned to Arm(s): PLD
B: Arm Label: AMG 386; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: AMG 386 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: AMG 386 Placebo, Drug: Paclitaxel | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): AMG 386 | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): AMG 386 Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): AMG 386 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): AMG 386 Placebo
C: Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B